The review proposes that histamine‑degrading probiotics (e.g., L. plantarum) reduce inflammation in IBD, but the cited evidence ([47], [48], [49]) is exclusively from in vitro cheese/miso fermentation or food matrix studies. There is no in vivo human data showing that oral administration of these strains lowers intestinal histamine levels or improves clinical endpoints in IBD patients. Extrapolating food microbiology to a chronic inflammatory disease is a major translational leap that is not justified.
The claim that probiotics enhance vitamin D absorption and metabolism is supported by references [60] (osteoporotic mice), [62] (healthy mice), and [63] (colitis mice). No human IBD study is cited. Given that active IBD alters mucosal permeability, VDR expression, and immune cell function, findings from non‑IBD or healthy models cannot be assumed to apply. This is a classic case of over‑extrapolation that weakens the clinical relevance of the proposed mechanism.
The section Role of probiotics in preventing IBD cites epidemiological associations (fermented food consumption) and animal models, but not a single randomized controlled trial for primary prevention in humans. The review presents this as a promising strategy without acknowledging that the evidence is purely correlational and hypothesis‑generating. This misrepresents the strength of the evidence.